Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database.

Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print Cited Medium: Internet ISSN: 1753-0407 (Electronic) Linking ISSN: 17530407 NLM ISO Abbreviation: J Diabetes Subsets: MEDLINE

Original Publication: Richmond, Vic. : Blackwell Publishing Asia, 2009-

Diabetes Mellitus, Type 2*/epidemiology ; Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use; Adult ; Humans ; United States/epidemiology ; Retrospective Studies ; Suicide, Attempted ; Prospective Studies ; Hypoglycemic Agents/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists

Objective: To assess the association between glucagon-like peptide-1 receptor agonists (GLP-1RA) treatment and the risk of suicide attempts in people with type 2 diabetes (T2D), with a focus on subgroups with and without a history of depression or suicide attempts.
Methods: This retrospective cohort study utilized TriNetX, a federated network of real-world data. Using the Global Collaborative Network data, we collected electronic medical records from 113 health care organizations with 135 million patient records with 8 million with T2D, 83% from the United States. The four cohorts were identified based on age, medication, diagnosis, and presence of depression or suicide attempts. Analytic methods included measures of association and number of Instances, with propensity score matching employed to mitigate potential confounders. The primary outcome was the incidence of suicide attempts among people with T2D with GLP-1RA treatment in comparison with dipeptidyl peptidase-4 inhibitor (DPP-4i) treatment.
Results: People with T2D treated with GLP-1RA consistently exhibited a lower risk of suicide attempts compared to those treated with DPP-4i. This was particularly significant in people with a history of depression or suicide attempts. The risk and odds ratios were significantly lower in the GLP-1RA-treated cohorts than in DPP-4i across all analyses.
Conclusion: As compared with DPP-4i, our analysis shows a protective effect associated with GLP-1RA treatment on the risk of suicide attempts among people with T2D. However, further research, particularly prospective and randomized studies, is necessary to confirm these observations and understand the underlying mechanisms.
(© 2024 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)

Brain Sci. 2023 Oct 24;13(11):. (PMID: 38002464)
Cell Metab. 2024 Jan 2;36(1):130-143.e5. (PMID: 38113888)
Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. (PMID: 28386912)
Nat Med. 2024 Jan;30(1):168-176. (PMID: 38182782)
Mol Metab. 2021 Apr;46:101090. (PMID: 32987188)
J Neurosci. 2011 Apr 27;31(17):6587-94. (PMID: 21525299)
Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243. (PMID: 34176426)
Curr Atheroscler Rep. 2022 Aug;24(8):643-654. (PMID: 35624390)
BMJ. 2023 Dec 8;383:2906. (PMID: 38084503)
Eur Psychiatry. 2023 Nov 30;66(1):e99. (PMID: 38031404)
J Diabetes. 2024 Mar;16(3):e13547. (PMID: 38501220)

Keywords: DPP-4 inhibitors; GLP-1RA; comparative analysis; depression; diabetes mellitus; retrospective cohort study; suicide attempts

0 (Hypoglycemic Agents)
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Glucagon-Like Peptide-1 Receptor)

Date Created: 20240319 Date Completed: 20240320 Latest Revision: 20240321

20240321

PMC10949079

10.1111/1753-0407.13547

38501220